Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
273 results about "Tumor immunity" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tumor immunity is the immune system's response to tumors, abnormal cell growths arising in the body. There is some scientific evidence to support theories that the body has some natural tumor immunity, depending on the type of tumor involved, as some tumors can spontaneously regress without medical treatment.
Anti-PD-L1 antibodies, compositions and articles of manufacture
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:F HOFFMANN LA ROCHE & CO AG
Anti-pd-l1 antibodies and their use to enhance t-cell function
ActiveUS20100203056A1Reduce level of pathogenChronic infectionAntibacterial agentsOrganic active ingredientsT-cell dysfunctionPD-L1
The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:F HOFFMANN LA ROCHE & CO AG
Anti-pd-l1 antibodies and uses thereof
ActiveUS20140341917A1Function increaseUpregulate cell-mediated immune responsesOrganic active ingredientsPeptide/protein ingredientsAntigen Binding FragmentAntigen binding
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Owner:MERCK PATENT GMBH
Methods of using Anti-pd-l1 antibodies and their use to enhance t-cell function to treat tumor immunity
InactiveUS20130045201A1Antibacterial agentsOrganic active ingredientsDiseaseAntiendomysial antibodies
The present application relates to methods of using anti-PD-L1 antibodies to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
Owner:GENENTECH INC
Anti-PD-L1 antibodies and uses thereof
ActiveUS9624298B2Function increaseUpregulate cell-mediated immune responsesNervous disorderPeptide/protein ingredientsAntigen Binding FragmentPD-L1
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.
Owner:MERCK PATENT GMBH
Molecular lymphatic mapping of sentinel lymph nodes
ActiveUS20050142556A1Luminescence/biological staining preparationSugar derivativesAbnormal tissue growthRadioactive tracer
The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye / radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and / or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
Owner:JOHN WAYNE CANCER INST
T cell regulation
InactiveUS20060240024A1Increases magnitudeSimple methodAntibacterial agentsNervous disorderRegulatory T cellAutoimmune responses
Regulatory T cells (Treg) limit autoimmunity but can also attenuate the magnitude of anti-pathogen and anti-tumor immunity. Understanding the mechanism of Treg function and therapeutic manipulation of Treg in vivo requires identification of Treg selective receptors. A comparative analysis of gene expression arrays from antigen specific CD4+ T cells differentiating to either an effector / memory or a regulatory phenotype revealed Treg selective expression of LAG-3 (CD223), a CD4-related molecule that binds MHC class II. LAG-3 expression on CD4+ T cells correlates with the cells' in vitro suppressor activity, and ectopic expression of LAG-3 on CD4 T cells confers suppressor activity on the T cells. Antibodies to LAG-3 inhibit suppression both in vitro and in vivo. LAG-3 marks regulatory T cell populations and contributes to their suppressor activity.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC +1
Targeted costimulatory polypeptides and methods of use to treat cancer
InactiveUS20110223188A1Function increaseIncreased rotational freedomAntibacterial agentsOrganic active ingredientsBinding domainWilms' tumor
Compositions are provided that are targeted to tumors or tumor-associated neovasculature and enhance the function of tumor-infiltrating T cells. The compositions include fusion proteins that contain a T cell binding domain and a tumor / tumor-associated neovasculature targeting domain. The fusion proteins optionally contain a peptide / polypeptide linker domain and a domain that mediates dimerization or multimerization. The T cell binding domain can be a costimulatory molecule. Methods for using the fusion proteins to enhance an immune response are provided. Therapeutic uses for the disclosed compositions include the induction of tumor immunity.
Owner:AMPLIMMUNE
Immuno-Oncolytic Therapies
ActiveUS20160235793A1Reduced responseImprove immunityViral antigen ingredientsUnknown materialsAbnormal tissue growthInterleukin-18 binding protein
The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and / or reduce host immunity and / or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and / or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
Owner:UNIVERSITY OF PITTSBURGH
Methods and Compositions for Infusion of Transiently Engrafting, Selected Populations of Allogeneic Lymphocytes to Treat Cancer
ActiveUS20150132290A1Improve anti-tumor effectPromoting homeostatic expansionBiocideDead animal preservationAbnormal tissue growthRegulatory T cell
The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Humanized anti-CD47 monoclonal antibody and application thereof
ActiveCN110872348AGrowth inhibitionBlocking the "Don't Eat Me" SignalImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsHuman tumorAntiendomysial antibodies
The invention relates to the technical field of antibody drugs, in particular to a humanized anti-CD47 monoclonal antibody and an application thereof. The humanized anti-CD47 monoclonal antibody provided by the invention can effectively inhibit tumor growth, dose-dependently block the binding of human SIRP alpha and human CD47, promote the phagocytosis effect of macrophages on tumor cells, preventthe tumor cells from evading a defense system of tumor immunity, and play an anti-tumor role; the monoclonal antibody can block the binding of the CD47 on the surfaces of the tumor cells and the SIRPalpha on the surfaces of the macrophages, block a ''do not eat me'' signal of the tumor cells, promote the recognition and uptake of the tumor cells by the macrophages, and promote the progress of phagocytizing the tumor cells; and the binding of the CD47 on the surfaces of the tumor cells and the SIRP alpha on the surfaces of the macrophages is a universal ''do not eat me''signal, and the CD47 can be used as a very promising target in the tumor immune system, and can play a powerful and effective role in human tumor treatment.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD
Use of cationic lipids to generate anti-tumor immunity
InactiveUS20050176672A1Stimulating cellular responseEfficient inductionOrganic active ingredientsAntipyreticLipid formationAbnormal tissue growth
A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.
Owner:GENZYME CORP +1
Protective immunity or immunological tolerance induced with RNA particularly total cellular RNA
InactiveUS7015204B1Reducing and inhibiting growth of tumorPathogen infection can be reduced and inhibitedBiocideSugar derivativesAbnormal tissue growthCuticle
Effective anti-tumor immunity is induced in mice utilizing RNA-pulsed epidermal cells (EC) for in vivo immunization or by injecting RNA intradermally into naïve mice. A vaccine comprising total cell RNA and a pharmaceutically acceptable carrier for inducing an immune response to reduce or prevent the occurrence of a tumor.
Owner:CORNELL RES FOUNDATION INC
Humanized nanometer antibody resistant to PD-L1 and application thereof
ActiveCN109096396AImmunoglobulins against cell receptors/antigens/surface-determinantsRadioactive preparation carriersDiseaseMedicine
The invention provides a humanized nanometer antibody resistant to PD-L1 and application thereof and particularly provides a nanometer antibody resistant to a protein programmed-death ligand (PD-L1).The provided nanometer antibody resistant to PD-L1 can effectively interdict the combination between the PD-L1 and programmed death molecules 1 (PD-1), and therefore an inhibiting effect of the PD-L1on T cells capable of expressing the PD-1 can be successfully counteracted. The PD-L1 nanometer antibody can be applied to prevention, diagnoses and treatment of diseases correlated with the PD-L1. The invention also provides a humanized PD-L1 nanometer antibody sequence, and the humanized nanometer antibody still has the function of interdicting the combination between the PD-L1 and the PD-1, ishigh in affinity and specificity and can serve as a tumor immunity target antibody drug.
Owner:HUALAN BIOLOGICAL ENG INC +1
KIR and ligand genetic typing experimental method
InactiveCN108624665ASmall sample sizePromote amplificationMicrobiological testing/measurementDiseaseNatural Killer Cell Inhibitory Receptors
The invention discloses a KIR and ligand genetic typing experimental method. By the technology, the time and labor are saved, and meanwhile, DNA sample capacity is further saved. A multi-PCR technology is adopted, meanwhile, 36 pairs of primers are further combined according to the sizes of PCR products, and finally, amplified reaction is finished in 12 reaction holes. The KIR and ligand genetic typing experimental method is conveniently applied to amplification of 96 pore plates, conventional Taq enzyme is used, typing of all KIR genes and ligands thereof can be finished at a time under the same reaction conditions, and the practicality of the KIR and ligand genetic typing experimental method is greatly improved. Two pairs of primers are used for a KIR gene, the accuracy is improved, anda false negative result is avoided. The KIR gene can be combined to MHC-I type ligand molecules on the surfaces of targeting cells, inhibiting or activating signals are transmitted to regulate the activity of NK cells and T cells, and the KIR and ligand genetic typing experimental method plays an important regulation role in hematopoietic stem cell transplantation, feto-matemal tolerance, anti-infectious immunity, tumor immunity and autoimmune diseases. Therefore, KIR genetic typing facilitates understanding of influences of KIR to tumor immunity, hematopoietic stem cell transplantation and autoimmune diseases.
Owner:韩瑜
Checkpoint Blockade and Microsatellite Instability
InactiveUS20170267760A1High mutational burdenMicrobiological testing/measurementDigestive systemProgrammed deathImmune tolerance
Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
MYBL2 epitope peptides and vaccines containing the same
InactiveCN102119170APeptide/protein ingredientsVaccination/ovulation diagnosticsTesticular stromal tumorHLA-A24
Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from MYBL2 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the MYBL2 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and / or prophylaxis of (i.e., preventing) cancers (tumors), and / or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the MYBL2 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, testicular tumor, pancreatic cancer, bladder cancer, non-small cell lung cancer, small cell lung cancer and esophageal cancer.
Owner:ONCOTHERAPY SCI INC
PD-L1 targeting polypeptide and application thereof
ActiveCN108840923APromote degradationReduce interactionPeptide/protein ingredientsGenetic engineeringProtein targetPD-L1
The invention provides PD-L1 protein targeting polypeptide, isolated nucleic acid, a nucleic acid construct, a recombinant expression vector and an antitumor medicine, and further provides applicationof the PD-L1 protein targeting polypeptide to preparation of the antitumor medicine. The polypeptide has the function of regulating PD-L1 protein, and can reduce the expression quantity of the PD-L1protein in cells, reduce the PD-1 protein bonding ability of tumor cells, increase the tumor cell killing ability of T cells and inhibit the in-vivo growth of the tumor cells. Different from the current commonly-used antibody blocking method, a technical scheme provided by the invention is beneficial to activation of T cell immune response and improvement on tumor immunity, is a new breakthrough as a tumor immunotherapeutic method, and has a wide meaning in biomedical and pharmaceutical research in allusion to PD-L1 regulation and control.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Ttk peptides and vaccines including the same
InactiveCN102459314ATumor rejection antigen precursorsPeptide/protein ingredientsNucleotidePeptide vaccine
Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the TTK gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing as active ingredients peptides derived from TTK or polynucleotides encoding the peptides. Furthermore, the present invention provides methods for the treatment and / or prophylaxis (i.e., prevention) of cancers (tumors), and / or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from TTK, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.
Owner:ONCOTHERAPY SCI INC
Isolated recombinant oncolytic poxvirus, pharmaceutical composition and use thereof in the treatment of tumors and/or cancer
ActiveCN109554353AFull play killGive full play to the anti-tumor immune effectPeptide/protein ingredientsPharmaceutical delivery mechanismPharmaceutical drugImmune Stimulation
The invention provides isolated recombinant oncolytic poxvirus, a pharmaceutical composition and use thereof in the treatment of tumors and / or cancer. The isolated recombinant oncolytic poxvirus is TKgene and the VGF gene functionally deficient type, an exogenous IL-21 gene is integrated in the genome of the recombinant oncolytic poxvirus, and the IL-21 gene can be expressed in tumor cells. The recombinant oncolytic poxvirus can be selectively replicated in tumor cells, and can fully exert the anti-tumor immunity of the exogenous IL-21, so that the oncolytic killing effect of the oncolytic virus and the anti-tumor immune stimulation effect of IL-21 can produce a synergistic effect.
Owner:HANGZHOU CONVERD CO LTD
Antitumor agents with the use of hsv
InactiveUS20050249705A1High ability to activate lymphocyteEnhance antigen presentationBiocideGenetic material ingredientsAbnormal tissue growthDendritic cell
It is intended to provide highly safe antitumor agents which exhibit an antitumor effect on human remote tumors such as metastatic tumors too and by which an antitumor immune reaction enabling an immune therapy for cancer can be induced, tumor immunity inducers, T cell activators, dendritic cell activators, a method of treating cancer using the same, etc. Inactivated herpes simplex virus (inactivated HSV), herpes simplex virus glycoprotein D (HSVgD), etc. are employed as the active ingredients of antitumor agents, tumor immunity inducers, T cell activators or dendritic cell activators. As a specific example of the treatment for the above-described inactivation, citation may be made of a combination of UV-irradiation using ultraviolet light at 254 nm at 4 J / m2 for 30 minutes with heating at 56° C. for 30 minutes.
Owner:INST OF GENE & BRAIN SCI
Modulation and control of SENP1 phosphorylated modified compound and SIRT3 SUMOylation modified compound and application of SENP1 phosphorylated modified compound and SIRT3 SUMOylation modified compound
InactiveCN108144062AIncrease awarenessNervous disorderPeptide/protein ingredientsDiseasePhosphorylation
The invention discloses SUMOylation modification which can be carried out at the K288th site of deacetylase SIRT3 dependent on NAD in a mitochondrion as well as modulation and control of activity of SIRT3; meanwhile, SUMO specific protease 1 (SENP1) can modulate and control SUMOylation modification of the SIRT3, so that related physiological and pathological processes in which SIRT3 participatingof mitochondrion are modulated and controlled; the modulation and control effect of the SENP1 depends on phosphorylated modification of an SENP1S180 site. The invention discloses the influence of a signal modulation and control path of an SENP1-SIRT3 shaft on metabolism of the mitochondrion, the activation of macrophage and T cells, and tumor immunity and tumor growth; therefore, a significance onprevention and treatment of diseases related with mitochondria metabolism and tumor is realized.
Owner:SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Tumor immunity type nutritional composition and application thereof
InactiveCN105410932APromote growthPrevent proliferationVitamin food ingredientsFood ingredient functionsTremellaHigh energy
Owner:BEIJING SAISHENG PHARMA
Checkpoint Blockade and Microsatellite Instability
InactiveUS20170313775A1Microbiological testing/measurementDigestive systemProgrammed deathImmune tolerance
Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE
Preparation method of PD-1 (Programmed cell death protein 1) and CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) double-gene defect type T lymphocyte preparation
InactiveCN107384959AReduce mortalityEfficiently obtainedGenetically modified cellsBlood/immune system cellsEnzyme digestionT lymphocyte
The invention belongs to the technical field of molecular biology and in particular relates to a preparation method of a PD-1 (Programmed cell death protein 1) and CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) double-gene defect type T lymphocyte preparation. Construction of a PD-1 and CTLA4 double-gene knockout vector, T lymphocyte separation and activation, electric transfection of T lymphocytes and T7E1 enzyme digestion identification, and flow cytometer screening and sequencing analysis are carried out. According to the production of a gene defect type immune cell preparation, on one hand, a production procedure of cells is simplified; on the other hand, the capability of killing tumor cells by the T lymphocytes is improved and the long-period tumor immunity can be enhanced.
Owner:山东百福基因科技有限公司 +1
Natural killer cell modified by specific chimeric antigen receptor gene and preparation method and use thereof
ActiveCN107893055AIncreased ability to activate downstream signalingStrong specific lethalityGenetically modified cellsTransferasesAntigenEphA Receptors
The invention discloses a natural killer cell modified by specific chimeric antigen receptor gene and a preparation method and use thereof. The natural killer cell modified by specific chimeric antigen receptor gene comprises a NY-ESCO-1 specific chimeric antigen receptor gene and a truncated spleen tyrosine kinase Syk gene. The preparation method simultaneously infects the natural killer cell with a slow virus containing the NY-ESCO-1 specific chimeric antigen receptor gene and a slow virus containing the truncated spleen tyrosine kinase Syk gene. By the combined action of the NY-ESCO-1 specific chimeric antigen receptor gene and the truncated spleen tyrosine kinase Syk gene, the natural killer cell modified by the specific chimeric antigen receptor gene improves the targeted tumor cell specific lethality of the natural killer cell, improves the ability of activating downstream signals of the natural killer cell, avoids the escape of tumor immunity, and accordingly enhances the killing activity on the tumor cell.
Owner:SHENZHEN MORECELL BIOMEDICAL TECH DEV CO LTD
Use of Post-Transplant Cyclophosphamide Treated Allogeneic Marrow Infiltrating Lymphocytes to Augment Anti-Tumor Immunity
InactiveUS20150320798A1Reduced toxicity and mortalityStrong specificityBiocideOrganic active ingredientsTreatment fieldLymphocyte
The present invention relates to the field of cancer therapy. More specifically, the present invention provides methods and compositions useful for augmenting anti-tumor immunity. In one embodiment, a method for treating or preventing post-allogeneic transplant relapse in a subject who has received post-transplant cyclophosphamide treatment comprises the steps of (a) obtaining a bone marrow sample from the subject; (b) expanding the marrow infiltrating lymphocytes (MILs) present in the sample; and (c) administering the MILs to the subject. In a specific embodiment, the method significantly reduces the likelihood of developing GVHD.
Owner:WINDMIL THERAPEUTICS INC
Method and composition for regulating the activity of regulatory t cells
InactiveUS20060121029A1High activitySuppression of rejection and graft-versus-host reactionsPeptide/protein ingredientsGenetic material ingredientsGraft versus host reactionsAntigen
The present invention provides a composition and method of regulating the activity of regulatory T cells. The present invention relates to a composition containing an antigen recognized by CD4+CD25+ regulatory T cells or an expression vector encoding such an antigen and a method of controlling an immune response from a mammal by administrating the composition to the mammal. Furthermore, the present invention provides effective means for suppressing a rejection reaction and a graft-versus-host reaction in transplantation and for prevention and treatment of an autoimmune disease or an allergic disease. Furthermore, an immunosuppression condition can be removed by the administration of Interferon-γ or a combination of Interleukin 12 and Interleukin 18. In other words, those cytokine actions and the sensitization with an SEREX antigen are suitably combined to artificially manipulate regulatory T cells, allowing the cells to be applied to an autoimmune disease, reactions accompanied with organ transplantation, allergic reaction, control of tumor immunity, and the like.
Owner:IMMUNOFRONTIER
Tumor antigen loaded polydopamine nanoparticles, and preparation method and application thereof
ActiveCN111346236AGood biocompatibilityThe preparation method is simple and gentlePowder deliveryCancer antigen ingredientsAdjuvantTumor antigen
The invention relates to a tumor antigen loaded polydopamine nanoparticle, and a preparation method and an application thereof. The tumor antigen loaded polydopamine nanoparticle is prepared by covalently connecting a tumor antigen to the surface of a polydopamine nanoparticle through Michael addition and Schiff base reaction, wherein the tumor antigen comprises, but is not limited to, one or moreselected from the group consisting of a specific tumor antigen peptide fragment, a tumor cell lysate, a specific tumor antigen DNA fragment and an adjuvant CpG. The tumor antigen loaded polydopaminenanoparticle prepared by using the method provided by the invention has good biocompatibility, can effectively activate in-vivo anti-tumor immunity, significantly inhibits the growth of tumor cells, can improve the tumor immunosuppressive microenvironment, further enhances the anti-tumor activity of the human body, can be used for immune treatment of tumors, and is simple and pollution-free in preparation method.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Compound I and compound II as well as preparation methods and application thereof
ActiveCN105315281AHas the effect of immune adjuvantImprove anti-tumor effectOrganic active ingredientsImmunoglobulin superfamilyMelanomaChemical compound
The invention relates to a compound I and a compound II as well as preparation methods and application thereof. The newly synthesized compound shown in the formula I can stimulate anti-tumor congenital immunity and cellular immunity while greatly improving the anti-tumor effect of ethacrynic acid (EA) and drug design of anti-tumor immunity synergetic integration is explored; the anti-melanoma immune response mechanism of the compound shown in the formula I is proved; the compound shown in the formula II and prepared through covalence of the compound shown in the formula I and ROR1 obviously reduces growth of breast cancer subcutaneously transplanted tumors, the breast cancer treatment immune response mechanism of the compound shown in the formula II is proved, and meanwhile, the fact that the compound shown in the formula I not only has the functions of stimulating congenital immunity and adaptive immunity, but also has the effect of immune adjuvant is proved.
Owner:SHENZHEN UNIV +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com